COMMUNIQUÉS West-GlobeNewswire
-
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
04/11/2024 - 14:30 -
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
04/11/2024 - 14:30 -
Parity Healthcare Analytics joins Synova to support safe, financially sustainable nurse staffing
04/11/2024 - 14:30 -
IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies List for 2024
04/11/2024 - 14:30 -
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
04/11/2024 - 14:30 -
Renovaro Issues Shareholder Letter and Provides Corporate Update
04/11/2024 - 14:31 -
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
04/11/2024 - 14:39 -
Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease
04/11/2024 - 14:57 -
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
04/11/2024 - 15:00 -
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
04/11/2024 - 15:00 -
SoldierStrong, USC Institute for Creative Technologies Sign License Agreement for Battle Buddy
04/11/2024 - 15:00 -
VitalHub Announces Q3 2024 Conference Call Date
04/11/2024 - 15:00 -
AAMI Updates Standard on Hospital use of Ethylene Oxide, Chemical Sterilization
04/11/2024 - 15:06 -
Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award
04/11/2024 - 15:30 -
KFSHRC Wins Gold and Four Bronze Stevie® Awards for Innovative Recruitment Strategies
04/11/2024 - 15:51 -
Nous sommes maintenant Percée DT1 – l’organisation auparavant connue sous le nom de FRDJ Canada change de nom pour reconnaître l'impact du diabète de type 1 sur les Canadiennes et Canadiens de tous âges
04/11/2024 - 16:00 -
We are now Breakthrough T1D™ – the organization formerly known as JDRF Canada rebrands to recognize impact of type 1 diabetes on Canadians of all ages
04/11/2024 - 16:00 -
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
04/11/2024 - 13:00 -
Opthea to Participate in November Investor Conferences
04/11/2024 - 13:00
Pages